Validation of a New Low-Cost, Methanol-Based Fixative for Cervical Cytology and Human Papillomavirus Detection
Nenhuma Miniatura disponível
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
KARGER
Autores
SILVA, Thais
NAUM, Bruna
CANAVEZ, Flavio
CANAVEZ, Juliana
CAMARA-LOPES, Luiz Heraldo
Citação
ACTA CYTOLOGICA, v.62, n.5/Jun, p.393-396, 2018
Resumo
Objective: To test the performance of a new fixative for pap smear collection for liquid-based cervical cytology, CellPreserv (R) and compare it with the commercially available, PreservCyt (R) used in the diagnosis and detection of human papillomavirus (HPV). Methods: Seven hundred twenty five women participated in this study after signing an informed consent. The specimens were collected using a traditional device, agitated in PBS, and equally divided in both fixatives. The slides were prepared routinely, stained by Papanicolaou, examined blindly by 2 cytologists, and reviewed by one cytopathologist. To search for HPV, 1,000 mu L from each fixative was taken and processed by polymerase chain reaction. Results: Considering the adequacy of samples, both fixatives had similar results - 0.33 and 0.32% of the cases unsatisfactory for PreservCyt (R) and CellPreserv (R), respectively. Considering the 701 satisfactory cases and comparing the new fixative to the traditional fixative, there was 99.3% concordance between both. The results regarding the HPV detection was 100% concordant between the 2 fixatives. Conclusion: The new methanol-based fixative, CellPreserv (R), is cheaper and equally efficient for treating cervical cancer screening and for HPV detection, and can be safely used by the health system prevailing in low-income countries. (C) 2018 S. Karger AG, Basel
Palavras-chave
Liquid-based cytology, ThinPrep, CellPreserv, Human papillomavirus, Cervical intraepithelial neoplasia
Referências
- Albrow R, 2012, CANCER CYTOPATHOL, V120, P87, DOI 10.1002/cncy.20203
- Beal CM, 2014, SALUD PUBLICA MEXICO, V56, P492
- Beerman H, 2009, GYNECOL ONCOL, V112, P572, DOI 10.1016/j.ygyno.2008.12.012
- Colgan TJ, 2004, CANCER CYTOPATHOL, V102, P362, DOI 10.1002/cncr.20656
- Cox JT, 2009, J CLIN VIROL, V45, pS3, DOI 10.1016/S1386-6532(09)70002-2
- Fremont-Smith M, 2004, CANCER CYTOPATHOL, V102, P269, DOI 10.1002/cncr.30599
- Karnon J, 2004, HEALTH TECHNOL ASSES, V8, P1
- Longatto A, 2015, ACTA CYTOL, V59, P273, DOI 10.1159/000435801
- Nayar R, 2015, CANCER CYTOPATHOL, V123, P271, DOI 10.1002/cncy.21521
- Payne N, 2000, Health Technol Assess, V4, P1
- Qu WM, 1997, J CLIN MICROBIOL, V35, P1304
- ROZEMEIJER K, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/BMJ.J504
- Rozemeijer K, 2016, CANCER CAUSE CONTROL, V27, P15, DOI 10.1007/s10552-015-0678-1
- Siebers AG, 2009, JAMA-J AM MED ASSOC, V302, P1757, DOI 10.1001/jama.2009.1569
- Simion N, 2014, ROM J MORPHOL EMBRYO, V55, P1331
- Stoler MH, 2001, JAMA-J AM MED ASSOC, V285, P1500, DOI 10.1001/jama.285.11.1500
- Weintraub J, 2000, DIAGN CYTOPATHOL, V22, P52, DOI 10.1002/(SICI)1097-0339(200001)22:1<52::AID-DC14>3.3.CO;2-R